81. A report should be submitted to the Vaccine Adverse Event Reporting System (VAERS) if a patient experiences a significant side effect after the administration of:
Answer: A
A report should be submitted to the Vaccine Adverse Event Reporting System (VAERS) if a patient experiences a significant side effect after the administration of Twinrix.
Submitting a report to the Vaccine Adverse Event Reporting System (VAERS) is necessary when significant side effects occur after the administration of vaccines, such as Twinrix, which is a vaccine for hepatitis A and B.
A) Twinrix
Twinrix is a combined vaccine for hepatitis A and B. Given its classification as a vaccine, any significant adverse events following its administration should indeed be reported to VAERS, making this option correct.
B) Topamax
Topamax, or topiramate, is an anticonvulsant medication used to treat epilepsy and migraine. It is not a vaccine, and thus, adverse events related to this medication would not be reported to VAERS, making this option incorrect.
C) Tenormin
Tenormin, known generically as atenolol, is a medication used primarily for hypertension and heart-related conditions. Similar to Topamax, it is not a vaccine and does not warrant reporting to VAERS, rendering this option incorrect.
D) Tricor
Tricor, or fenofibrate, is a medication used to help lower cholesterol and triglyceride levels. Since it is not a vaccine, any significant side effects would not be reported to VAERS, making this option incorrect as well.
Conclusion
Twinrix is the only option listed that qualifies as a vaccine, necessitating reporting to VAERS for any significant adverse events. The other options, being non-vaccine medications, do not require such reporting, confirming Twinrix as the definitive correct answer.